A deal has been between the pharmaceutical company Pfizer, which is currently developing a vaccine for Coronavirus, and the United States government, securing a 100 million supply to be dispensed immediately after the vaccine is approved. The government can also add 500 million more units as part of the terms of the deal.
The first 100 million units are to be approved first by the US FDA for emergency use before it is handed to the possession of the government. Phase 3 clinical trials will still resume to be conducted by Pfizer and BioNTech to ensure overall safety and efficacy of the vaccine.
The Pfizer and BioNTech collaboration released initial positive results on their trial in Germany. BNT162b1 showed induced T cell responses against a Sars-CoV-2 virus strain, with mild to moderate adverse reactions that varied per dose.
Once the emergency use authorization is issued, the last 3 months of 2020 will be spent distributing the vaccines all over the United States. Recipients of the drugs will be decided by the government.
The Operation Warp Speed initiative of the US government comprised of the HHS, FDA, CDC, NIH, BARDA, and DoD, has laid out a strategy ”to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.” Or in general, referred to as countermeasures.
The program aims to gather as many vaccines as possible from various sources to be able to provide for the Americans who need it. The vaccine by Pfizer will be given for free to the people, along with other ones such as those from AstraZeneca and Novavax that are purchased by the government which could be given at a low cost or also entirely free. The same cannot be said for private healthcare providers.
According to Dr. Albert Bourla, CEO of Pfizer, says the company has decided to pursue mass production even before trial results so that by the time of approval for emergency use or positive clinical trials results, the vaccines will be ready, if not almost.